Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user reported significant hair regrowth and stopped hair loss after using Pyrilutamide and Minoxidil for four months. They found Pyrilutamide effective in blocking DHT locally without side effects, preferring a gray market version over Koshine's product.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

A user shared their 5-month hair loss treatment progress using oral finasteride, Regaine foam, 2DDR serum, and microneedling, noting improvements in hair growth at the crown and front. They are considering increasing microneedling frequency or adding a shampoo to their routine.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The conversation discusses concerns about getting a hair transplant with the potential release of a new treatment, PP405, which may regrow dormant hair follicles. The user is currently using Minoxidil, Derma, and Keto but is waiting to start finasteride or dutasteride.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A user shared their 5-month progress after a hair transplant with 3500 FUE grafts, using Minoxidil and Finasteride. They used oral Minoxidil at 5mg.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Fibrin hydrogels, when combined with stem cells, can induce hair follicle regeneration and show potential for treating alopecia. The study demonstrated successful hair growth in mice without adverse effects.

A 34-year-old from Patna shared a 5-month update on his hair transplant, which involved 4,200 grafts using the FUE technique to cover the front and mid-scalp. He experienced initial shock loss but now sees natural-looking growth and improved density.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

A 32-year-old shares 2-month progress using oral finasteride, topical minoxidil, and weekly derma stamping for hair loss, noting early improvements and no side effects. Encouragement is given for continued progress.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

A 22-year-old had a 3,500 graft hair transplant to restore his original hairline and improve density, while using dutasteride and oral minoxidil to manage hair loss. He believes being proactive with medication prevented further loss and allowed for a successful transplant.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

A user is considering starting spironolactone for androgenetic alopecia but is concerned about stopping it before pregnancy. Another user suggests trying topical treatments as an alternative.

The user shared progress pictures after 8 months of using oral finasteride and topical minoxidil for hair loss, noting a plateau and considering adding dutasteride and oral minoxidil. They experienced a shedding phase but saw some regrowth, and also use a derma stamp and GHK-CU injections.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The user has been using finasteride for years with little regrowth and recently started using Cécred edge drops, which have significantly improved their scalp condition. Another user mentioned combining Cécred with derma stamping for better results.

The user is discussing their hair regrowth progress after using oral Minoxidil (2mg daily) and Finasteride (1mg daily) for about five months, along with support supplements like Vitamin D, Biotin, and Omega 3. Suggestions include replacing Finasteride with Dutasteride and increasing Minoxidil dosage, while also considering microneedling and scalp massage for better results.